[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [QUIET] · [BUSINESS]

2 clusters · 2 sources · 23 days · First seen · Last updated

Celltrion biosimilar market expansion

Overview

Celltrion has demonstrated significant financial and market growth driven by its biosimilar portfolio. In its second-quarter 2025 results, the company reported sales of 1.3937 trillion won and an operating profit of 451.8 billion won, representing year-on-year increases of 45% and 86.3% respectively. This performance was largely supported by newer biosimilars, which accounted for 65% of total sales.

Expanding on this momentum, market data for the first quarter of 2024 indicates that Celltrion has secured dominant market shares for autoimmune and oncology biosimilars across several Asian markets. Products such as Remsima (infliximab) and Truxima (rituximab) achieved top market positions in Singapore, Hong Kong, Thailand, and Malaysia. The company attributes its success to direct sales networks through local subsidiaries and plans to further expand its portfolio in the region with new product launches.

Entities

Celltrion · IQVIA · Cardiol Therapeutics Inc. · Omlyclo · Samsung Biologics

Timeline

  1. 8 days ago

    [BUSINESS] 2 sources
    Celltrion secures leading market shares for biosimilars in Asia

    Celltrion has secured leading market shares for its Remsima and oncology biosimilars across Singapore, Hong Kong, Thailand, and Malaysia, driven by its direct sales networks.

  2. about 1 month ago

    [BUSINESS] 3 sources
    Celltrion posts record Q2 sales of 1.4 trillion won, driven by high‑margin biosimilars

    Celltrion reported Q2 sales of 1.4 trillion won (up 45% YoY) and operating profit of 452 billion won (up 86% YoY), with a 32.4% margin. New biosimilars made up 65% of sales, beating Samsung Biologics in revenue

Sources

biz.heraldcorp.com · kormedi.com